Skip to content
Medical Health Aged Care

Fear, fun and the neuroscience of Halloween: expert available for comment

Neuroscience Research Australia (NeuRA) < 1 mins read

Halloween's popularity in Australia is on the rise, with some people embracing the occasion for the spooky and the scary, while others have jumped on board for the dress-ups, lollies and fun. As people finalise their preparations for the spookiest night of the year, NeuRA Senior Research Fellow, Dr Steve Kassem, is available to discuss why we love being scared out of brains. 

Dr Kassem has qualifications in neuroscience and psychology and is passionate about science communication. His knowledge is matched by his enthusiasm for how the brain works.

Dr Kassem works in NeuRA's Brain Mapping Laboratory, a specialised facility that produces detailed atlases illustrating the regions and tracts of the human brain. Dr Kassem works to map the brain, to improve our understanding of the different regions of the brain, how they look and how they interact with each other.

 

 


About us:

Neuroscience Research Australia (NeuRA) is an independent, not-for-profit research institute based in Sydney aiming to prevent, treat and cure brain and nervous system diseases, disorders and injuries through medical research. To learn more about NeuRA: www.neura.edu.au


Contact details:

Katana Smith
Senior Media & PR Advisor
[email protected] | 0452 140 477

Media

More from this category

  • Medical Health Aged Care
  • 22/01/2026
  • 23:11
Concept Medical Inc.

Concept Medical Announces First Patient Enrollment in STARS DAPT Randomized Clinical Trial Evaluating Abluminus NP Polymer-Free DES

TAMPA, Fla.–BUSINESS WIRE– Concept Medical Inc., a global pioneer in innovative drug delivery technology, is proud to announce the successful enrollment of the first…

  • Contains:
  • Medical Health Aged Care
  • 22/01/2026
  • 22:11
Sinovac Biotech Ltd.

SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing

BEIJING--BUSINESS WIRE-- Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request to continue its listing on the Nasdaq Stock Market, subject to stated conditions focused on timely completion of its financial audit and remediation of filing delinquencies. Under the Panel’s decision, SINOVAC must, on or before May 11, 2026, demonstrate compliance with Nasdaq Listing Rule 5250(c)(1) and Listing Rule 5250(c)(2) by completing filings of its annual report for the year ended December 31, 2024 on Form 20-F and…

  • Medical Health Aged Care
  • 22/01/2026
  • 17:11
Galderma

IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio

At IMCAS 2026, Galderma will present findings supporting Sculptra’s® regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.